-
Mashup Score: 14
Cells carrying a monoallelic germline BRCA2 mutation can bypass Knudson’s “two-hit” requirement to initiate tumorigenesis when the glycolytic metabolite methylglyoxal transiently disables BRCA2 function. Metabolic bypass of tumor suppressor activity may link metabolic reprogramming, metabolic disorders, or diet to early steps in carcinogenesis.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Rough Sleepers: Dr. Jim O'Connell's urgent mission to bring healing to homeless people - 1 month(s) ago
Rough Sleepers: Dr. Jim O’Connell’s urgent mission to bring healing to homeless people
Source: www.amazon.comCategories: General Medicine News, Hem/OncsTweet-
Loved "Rough Sleepers", an inspiring #book about a team of healthcare workers devoted to caring for the #homeless. Incredibly challenging work. The book's message is that no matter who you are taking care of, medicine is always about relationships. @BHCHP https://t.co/hKAc24zYKf
-
-
Mashup Score: 33RAS/RAF co-mutation and ERBB2 copy number modulates HER2 heterogeneity and responsiveness to HER2-directed therapy in colorectal cancer - 2 month(s) ago
Abstract. Purpose: ERBB2 amplified colorectal cancer (CRC) is a distinct molecular subtype with expanding treatments. Implications of concurrent oncogenic RAS/RAF alterations are not known. Experimental Design: Dana-Farber and Foundation Medicine Inc. CRC cohorts with genomic profiling were used to identify ERBB2 amplified cases (Dana-Farber, n = 47/2,729 [1.7%]; FMI, n = 1857/49,839 [3.7%]). Outcomes of patients receiving HER2-directed therapies are reported (Dana-Farber, n = 9; Flatiron Health-Foundation Medicine clinicogenomic database, FH-FMI CGDB, n = 38). Multi-site HER2 immunohistochemistry and genomic profiling were performed to understand HER2 intratumoral and interlesional heterogeneity. The impact of concurrent RAS co-mutations on the effectiveness of HER2-directed therapies were studied in isogenic CRC cell lines and xenografts. Results: ERBB2 amplifications are enriched in left-sided CRC. 20% of ERBB2 amplified CRCs have co-occurring oncogenic RAS/RAF alterations. While RA
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
In this collaboration with Harsh Singh, @LabSethi, @JLHornick we examined mechanisms of resistance and sensitivity to targeted therapy in #HER2 amplified #ColorectalCancer. https://t.co/V0ngfsVYFu @CCR_AACR
-
-
Mashup Score: 9A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis | NEJM - 3 month(s) ago
Original Article from The New England Journal of Medicine — A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
Surprising result! A thyroid hormone receptor β (THR-β) agonist appears effective in improving #NASH. Decreased THR-β activation promotes NASH by "reducing mitochondrial function and β-oxidation of fatty acids" which ultimately leads to fibrosis. https://t.co/uDFoY6XLPu
-
-
Mashup Score: 38Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders - 3 month(s) ago
Background Recent trials suggest that programmed cell death 1 (PD-1)-directed immunotherapy may be beneficial for some patients with anal squamous cell carcinoma and biomarkers predictive of response are greatly needed. Methods This multicenter phase II clinical trial ([NCT02919969][1]) enrolled patients with metastatic or locally advanced incurable anal squamous cell carcinoma (n=32). Patients received pembrolizumab 200 mg every 3 weeks. The primary endpoint of the trial was objective response rate (ORR). Exploratory objectives included analysis of potential predictive biomarkers including assessment of tumor-associated immune cell populations with multichannel immunofluorescence and analysis of circulating tumor tissue modified viral-human papillomavirus DNA (TTMV-HPV DNA) using serially collected blood samples. To characterize the clinical features of long-term responders, we combined data from our prospective trial with a retrospective cohort of patients with anal cancer treated wi
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet-
In our new paper, @BHuffmanMD did a wonderful job examining #PD1 immunotherapy in advanced #AnalCancer. Despite being an #HPV driven cancer, with persistent viral antigen production, there is a wide range of responses to anti-PD1 immunotherapy. https://t.co/OAoPTBZNU0
-
-
Mashup Score: 13Cabozantinib Efficacy Prompts CABINET Trial Unblinding in Advanced Pancreatic and Extra-Pancreatic NETs - 8 month(s) ago
Interim data from the phase 3 CABINET trial demonstrated significant improvement in progression-free survival with cabozantinib vs placebo in patients with advanced pancreatic or extra-pancreatic neuroendocrine tumors following progression on prior systemic therapy.
Source: www.onclive.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Thrilled to hear today’s announcement that the CABINET trial is positive with cabozantinib having efficacy in Pancreatic and Extra-Pancreatic #NeuroendocrineCancer Very happy for my @DanaFarber colleague Jen Chan. https://t.co/dQdtpW3gNx
-
-
Mashup Score: 2
Author links open overlay panel Esther Baranov MD, Jonathan A. Nowak MD, PhD Colorectal carcinoma (CRC) is the third most-commonly diagnosed cancer worldwide and the second largest contributor to cancer-related death. 1, 2 In addition, the incidence in individuals younger than 50 years of age (early-onset CRC) has increased steadily in recent years. 2 Since the original description of CRC pathogenesis as a stepwise series of linked molecular and morphologic events over 30 years ago, the burgeoning field
Source: www.sciencedirect.comCategories: Latest Headlines, Oncologists2Tweet-
RT @jonathan_nowak: Free online from #surgpathclinics for a limited time: https://t.co/S6bZ63pqF9 Exciting to see how KRAS inhibition an…
-
-
Mashup Score: 0Comparative analysis and isoform-specific therapeutic vulnerabilities of KRAS mutations in non-small cell lung cancer - 2 year(s) ago
Purpose: Activating missense mutations of KRAS are the most frequent oncogenic driver events in lung adenocarcinoma (LUAD). However, KRAS isoforms are highly heterogeneous, and data on the potential isoform-dependent therapeutic vulnerabilities are still lacking. Experimental design: We developed an isogenic cell-based platform to compare the oncogenic properties and specific therapeutic…
Source: Clinical Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
Insightful paper from @DrMarkAwad, Pasi Janne, and Chiara Ambrogio analyzing functional and genomic differences in #NSCLC tumors harboring different #KRAS mutant isoforms. https://t.co/VmuqiM66Oj
-
-
Mashup Score: 0
The stunning Covid vaccines manufactured by Pfizer-BioNTech and Moderna drew upon long-buried discoveries made in the hopes of ending past epidemics.
Source: www.nytimes.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Beautifully written article describing the decades of scientific advances that led to the development of the mRNA #COVID vaccines. https://t.co/AlRyQFQJ24
-
-
Mashup Score: 7Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers evaluated by clinical characteristics - 2 year(s) ago
Among patients with multiple primary cancers, the prevalence of germline pathogenic variants (PVs) in actionable cancer genes increases with the number of primary cancers (PCs): 13.1% with 2 PCs, 15….
Source: American Cancer Society JournalsCategories: Hem/Oncs, Latest HeadlinesTweet-
Data from this paper really drives home the point that patients w/ multiple cancers are a unique population. Pathogenic germline mutations were found in 13% of pts w/ 2 cancers and 18% of pts w/ 4 cancers. Germline screening is clearly needed in these pts. https://t.co/dN1o36qsla https://t.co/IStIX8NkGX
-
Very interesting paper that makes me think differently about how monoallelic loss of #BRCA2 can lead to #PancreaticCancer. https://t.co/wOr0R4UGcs